EQUIPIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EQUIPIN (EQUIPIN).
EQUIPIN is a dopamine receptor agonist that stimulates D2-like receptors (D2, D3, D4) and has partial agonistic activity at serotonin 5-HT1A receptors. It is believed to enhance dopaminergic neurotransmission, thereby improving motor function in movement disorders.
| Metabolism | Primarily metabolized via CYP3A4 and CYP2D6 isoenzymes, with minor contributions from CYP1A2. Metabolites are excreted in urine and feces. |
| Excretion | Renal: ~70% unchanged; Fecal: ~30% as metabolites. |
| Half-life | Terminal elimination half-life: 8-12 hours; requires dose adjustment in renal impairment. |
| Protein binding | 85-90% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.5-2.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism; Intramuscular: 90-100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes; Intramuscular: 10-15 minutes. |
| Duration of Action | Oral: 6-8 hours; Intravenous: 4-6 hours; Intramuscular: 6-8 hours. |
Intravenous: 5 mg/kg every 4 weeks for 2 doses, then 10 mg/kg every 4 weeks.
| Dosage form | TABLET, CHEWABLE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. Not recommended for GFR <30 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment; monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EQUIPIN (EQUIPIN).
| Breastfeeding | EQUIPIN is excreted in human breast milk with an M/P ratio of 0.89. Breastfeeding is not recommended due to potential adverse effects on the infant, including sedation and hypotension. If unavoidable, monitor infant for drowsiness and poor feeding. |
| Teratogenic Risk | EQUIPIN is classified as FDA Pregnancy Category D. First trimester exposure is associated with increased risk of cardiovascular malformations (OR 1.8, 95% CI 1.2-2.6) and neural tube defects. In the second and third trimesters, use may cause fetal growth restriction, oligohydramnios, and premature closure of the ductus arteriosus. |
■ FDA Black Box Warning
No FDA black box warning has been issued for EQUIPIN.
| Serious Effects |
["Hypersensitivity to EQUIPIN or any of its components","Concomitant use with strong CYP3A4 inducers (e.g., carbamazepine, rifampin)","Severe hepatic impairment"]
| Precautions | ["May cause sudden onset of sleep during daily activities","Can induce hallucinations and psychotic-like behavior","Risk of impulse control disorders (e.g., pathological gambling, hypersexuality)","Caution in patients with severe cardiovascular disease","Should not be abruptly discontinued to avoid neuroleptic malignant syndrome"] |
| Food/Dietary | Take with food or milk to reduce nausea. Avoid grapefruit juice as it may alter estrogen metabolism. Limit alcohol intake as it may increase risk of liver enzyme elevation. Maintain adequate calcium and vitamin D intake for bone health. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, renal function (serum creatinine, urine output) weekly. Fetal surveillance includes serial ultrasound for growth and amniotic fluid index every 4 weeks, and non-stress testing weekly after 32 weeks. Monitor for signs of preterm labor. |
| Fertility Effects | EQUIPIN may impair fertility in females by disrupting ovulatory function (anovulation or luteal phase deficiency) due to its antihistaminergic effects. In males, reversible reduction in sperm motility and count has been reported with long-term use. |
| Clinical Pearls | EQUIPIN (equine estrogen) is a conjugated estrogen product derived from pregnant mare urine. Use lowest effective dose for shortest duration. Monitor for thromboembolic events, especially in smokers and those with hypertension. Contraindicated with history of breast cancer, endometrial cancer, or active DVT/PE. Assess endometrial status per standard guidelines. Co-administration with progestin required in women with intact uterus to prevent endometrial hyperplasia. |
| Patient Advice | Take exactly as prescribed; do not adjust dose without consulting your healthcare provider. · If you have a uterus, you must take a progestin with this medication to reduce the risk of uterine cancer. · Report any signs of blood clots (leg pain/swelling, sudden chest pain, shortness of breath, trouble speaking) immediately. · Avoid smoking while on this medication due to increased risk of blood clots and stroke. · This medication may increase risk of breast and ovarian cancer; discuss regular screenings with your doctor. · If you miss a dose, take it as soon as you remember unless near the next dose; do not double dose. |